Is TuHURA Biosciences, Inc. (HURA) a Buy, Sell, or Hold?
NASDAQ : HURA
TuHURA Biosciences, Inc.
$2.25 USD
$0.03 (1.35%)
- Volume
- 162.49K
- Average Volume
- 661.92K
- Market Capitalization
- $143.29M
- P/E Ratio
- -3.67
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $3.90
- Year Low
- $0.41
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.15
| Source | Headline |
|---|---|
|
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for Acute Myeloid Leukemia (AML) The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026 TAMPA, Fla., June 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the study of its TBS-2025 VISTA inhibiting antibody for the treatment of molecularly defined subsets of AML and other blood related cancers. prnewswire.com - 2026-06-15 07:45:00 |
|
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended March 31, 2026, and provided a corporate update. prnewswire.com - 2026-05-15 17:00:00 |
|
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced James A. prnewswire.com - 2026-05-12 07:30:00 |
|
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestones TAMPA, Fla., April 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a loan agreement providing a credit facility of up to $50 million in funding to support the Company's pipeline, ongoing clinical trials, and general corporate expenses. prnewswire.com - 2026-04-22 07:30:00 |
